Microsoft Excel LibreOffice Calc

Eli Lilly & Co. (LLY)

Income Statement
Quarterly Data

Difficulty: Beginner

The income statement presents information on the financial results of a company’s business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Eli Lilly & Co., Consolidated Income Statement (quarterly data)

USD $ in thousands

Microsoft Excel LibreOffice Calc
3 months ended Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Revenue 5,636,700  5,092,200  6,438,600  6,061,900  6,355,200  5,700,000  6,160,700  5,658,000  5,824,300  5,228,300  5,760,500  5,191,700  5,404,800  4,865,100  5,375,600  4,959,700  4,978,700  4,644,700  5,121,300  4,875,600  4,935,600  4,683,100 
Cost of sales (1,124,900) (1,138,700) (1,593,700) (1,562,300) (1,702,700) (1,571,300) (1,624,800) (1,566,100) (1,551,600) (1,327,700) (1,466,000) (1,400,900) (1,465,000) (1,323,000) (1,389,200) (1,236,900) (1,218,400) (1,192,700) (1,253,100) (1,267,000) (1,189,700) (1,222,700)
Gross margin 4,511,800  3,953,500  4,844,900  4,499,600  4,652,500  4,128,700  4,535,900  4,091,900  4,272,700  3,900,600  4,294,500  3,790,800  3,939,800  3,542,100  3,986,400  3,722,800  3,760,300  3,452,000  3,868,200  3,608,600  3,745,900  3,460,400 
Research and development (1,402,200) (1,230,500) (1,453,800) (1,343,300) (1,333,100) (1,176,900) (1,473,200) (1,319,400) (1,250,900) (1,238,300) (1,450,600) (1,236,400) (1,335,900) (1,221,000) (1,444,200) (1,143,400) (1,169,500) (1,039,300) (1,185,700) (1,243,200) (1,195,400) (1,109,300)
Marketing, selling, and administrative (1,586,300) (1,517,100) (1,861,500) (1,616,600) (1,653,700) (1,500,000) (1,780,500) (1,555,500) (1,707,400) (1,544,700) (1,790,100) (1,565,400) (1,622,600) (1,473,900) (1,798,400) (1,575,700) (1,635,400) (1,523,500) (1,799,900) (1,672,100) (1,663,900) (1,484,900)
Acquired in-process research and development (25,000) (136,900) (329,400) (30,000) (1,624,500) —  (50,000) (205,000) —  (857,600) (30,000) —  —  —  (199,000) —  (80,000) (256,000) (105,200) (95,000) —  — 
Asset impairment, restructuring, and other special charges —  (423,900) (246,000) (83,300) (74,400) (78,300) (1,003,200) (406,500) (50,000) (213,900) (147,600) (45,500) (58,000) (131,400) (144,900) (42,400) (72,400) (108,000) (401,000) (36,300) —  (31,400)
Operating income (loss) 1,498,300  645,100  954,200  1,426,400  (33,200) 1,373,500  229,000  605,500  1,264,400  46,100  876,200  943,500  923,300  715,800  399,900  961,300  803,000  525,200  376,400  562,000  886,600  834,800 
Other, net, income (expense) (32,400) 86,000  (15,300) (15,400) 38,000  67,500  55,100  (13,900) (3,900) 15,100  15,800  27,200  21,200  (149,000) 44,700  86,500  (123,300) 92,700  137,200  93,500  53,800  56,000 
Income before income taxes 1,465,900  731,100  938,900  1,411,000  4,800  1,441,000  284,100  591,600  1,260,500  61,200  892,000  970,700  944,500  566,800  444,600  1,047,800  679,700  617,900  513,600  655,500  940,400  890,800 
Income taxes (138,700) (170,000) 186,100  (261,500) (264,700) (223,600) (1,941,000) (36,000) (252,500) (172,000) (120,200) (192,700) (196,800) (126,700) 33,800  (248,100) (78,900) (88,400) (85,100) (154,900) (206,900) (162,900)
Net income (loss) from continuing operations 1,327,200  561,100  1,125,000  1,149,500  (259,900) 1,217,400  (1,656,900) 555,600  1,008,000  (110,800) 771,800  778,000  747,700  440,100  478,400  799,700  600,800  529,500  428,500  500,600  733,500  727,900 
Net income from discontinued operations —  3,680,500  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Net income (loss) 1,327,200  4,241,600  1,125,000  1,149,500  (259,900) 1,217,400  (1,656,900) 555,600  1,008,000  (110,800) 771,800  778,000  747,700  440,100  478,400  799,700  600,800  529,500  428,500  500,600  733,500  727,900 

Based on: 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-05-01), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-30), 10-Q (filing date: 2015-04-30), 10-K (filing date: 2015-02-19), 10-Q (filing date: 2014-10-29), 10-Q (filing date: 2014-07-28), 10-Q (filing date: 2014-04-28).

Item Description The company
Revenue Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Eli Lilly & Co.’s revenue declined from Q4 2018 to Q1 2019 but then slightly increased from Q1 2019 to Q2 2019.
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Eli Lilly & Co.’s operating income (loss) declined from Q4 2018 to Q1 2019 but then increased from Q1 2019 to Q2 2019 exceeding Q4 2018 level.
Income before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Eli Lilly & Co.’s income before income taxes declined from Q4 2018 to Q1 2019 but then increased from Q1 2019 to Q2 2019 exceeding Q4 2018 level.
Net income (loss) The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Eli Lilly & Co.’s net income (loss) increased from Q4 2018 to Q1 2019 but then slightly declined from Q1 2019 to Q2 2019 not reaching Q4 2018 level.